Regarding pharmacogenetics and the response to MDD treatment with SSRIs, a study found that the genetic polymorphism rs1800544 in the DRD4 gene, which encodes the dopamine D4 receptor, demonstrated a significant link with the response to treatment after six weeks of SSRI use. The gene discussed is DRD4; the disease is major depressive disorder.